Home › Companies › ORAMED PHARMACEUTICALS INC. › 2024-2025
At ORAMED PHARMACEUTICALS INC.'s shareholder meeting held August 1, 2024, in the 2024-2025 proxy season, 61 asset managers reported how they voted on 9 ballot items in their SEC Form N-PX filings, covering 204 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding advisory basis, the compensation of the Company's Named Executive… — ORAMED PHARMACEUTICALS INC.'s filing reports the proposal as approved, with 90% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: ORAMED PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on August 2, 2024.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and ORAMED PHARMACEUTICALS INC.’s Form 8-K, filed August 2, 2024 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of August 1, 2024: 9 items on ORAMED PHARMACEUTICALS INC.’s Form 8-K, filed August 2, 2024: 7 elected · 2 approved.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2024-2025
Explore ORAMED PHARMACEUTICALS INC. in the interactive database Compare manager voting policies
These tallies are ORAMED PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed August 2, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Dr. Daniel Aghion | 10,090,486 | 117,471 | 54,544 | -- | 7,236,740 | 99% | Elected | — |
| Elect Director: Dr. Miriam Kidron | 10,011,623 | 211,627 | 39,251 | -- | 7,236,740 | 98% | Elected | — |
| Elect Director: Nadav Kidron | 10,007,284 | 216,146 | 39,071 | -- | 7,236,740 | 98% | Elected | — |
| Elect Director: Dr. Arie Mayer | 9,688,466 | 529,929 | 44,106 | -- | 7,236,740 | 95% | Elected | — |
| Elect Director: Yehuda Reznick | 10,050,385 | 138,618 | 73,048 | -- | 7,236,740 | 99% | Elected | — |
| Elect Director: Leonard Sank | 9,435,858 | 764,562 | 62,081 | -- | 7,236,740 | 93% | Elected | — |
| Elect Director: Benjamin Shapiro | 10,120,322 | 112,399 | 29,780 | -- | 7,236,740 | 99% | Elected | — |
| 2. Advisory Vote on the Compensation of the Company's Named Executive Officers | 9,171,779 | 1,016,334 | 74,388 | -- | 7,236,740 | 90% | Approved | — |
| 3. Ratification of Independent Registered Public Accounting Firm for the 2024 Fiscal Year | 17,323,361 | 119,546 | 56,334 | -- | -- | 99.3% | Approved | — |
Source: ORAMED PHARMACEUTICALS INC., Form 8-K, filed with the SEC on August 2, 2024 — read the filing on EDGAR.
Each item below shows how the 61 asset managers that disclosed a ORAMED PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 2 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: To re-elect the following directors of the Company to hold office until our next annual meeting of stockholders and until their respective successors shall be elected and qualified or until their earlier resignation or removal: Benjamin Shapiro
ORAMED PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Benjamin Shapiro”): 10,120,322 for, 112,399 against, per its Form 8-K filed August 2, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The stockholders re-elected the following directors of the Company to hold office until the next annual meeting of stockholders and until their respective successors shall be elected and qualified or until their earlier resignation or removal.”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 9 asset managers below reported 119,955 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 74,906 | 0 | 0 | 0 | For |
| Dimensional | 17,901 | 0 | 0 | 0 | For |
| State Street | 11,889 | 0 | 0 | 0 | For |
| American Century | 8,084 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 4,400 | 0 | 0 | 0 | For |
| Fidelity | 1,155 | 0 | 0 | 0 | For |
| Equitable | 711 | 0 | 0 | 0 | For |
| John Hancock | 697 | 0 | 0 | 0 | For |
| Guggenheim | 212 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Description as filed by funds: To re-elect the following directors of the Company to hold office until our next annual meeting of stockholders and until their respective successors shall be elected and qualified or until their earlier resignation or removal: Dr. Arie Mayer
ORAMED PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Dr. Arie Mayer”): 9,688,466 for, 529,929 against, per its Form 8-K filed August 2, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The stockholders re-elected the following directors of the Company to hold office until the next annual meeting of stockholders and until their respective successors shall be elected and qualified or until their earlier resignation or removal.”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 9 asset managers below reported 39,241 for, 80,714 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 0 | 74,906 | 0 | 0 | Against |
| Dimensional | 17,901 | 0 | 0 | 0 | For |
| State Street | 11,889 | 0 | 0 | 0 | For |
| American Century | 8,084 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 0 | 4,400 | 0 | 0 | Against |
| Fidelity | 1,155 | 0 | 0 | 0 | For |
| Equitable | 0 | 711 | 0 | 0 | Against |
| John Hancock | 0 | 697 | 0 | 0 | Against |
| Guggenheim | 212 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: To re-elect the following directors of the Company to hold office until our next annual meeting of stockholders and until their respective successors shall be elected and qualified or until their earlier resignation or removal: Dr. Daniel Aghion
ORAMED PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Dr. Daniel Aghion”): 10,090,486 for, 117,471 against, per its Form 8-K filed August 2, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The stockholders re-elected the following directors of the Company to hold office until the next annual meeting of stockholders and until their respective successors shall be elected and qualified or until their earlier resignation or removal.”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 9 asset managers below reported 119,955 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 74,906 | 0 | 0 | 0 | For |
| Dimensional | 17,901 | 0 | 0 | 0 | For |
| State Street | 11,889 | 0 | 0 | 0 | For |
| American Century | 8,084 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 4,400 | 0 | 0 | 0 | For |
| Fidelity | 1,155 | 0 | 0 | 0 | For |
| Equitable | 711 | 0 | 0 | 0 | For |
| John Hancock | 697 | 0 | 0 | 0 | For |
| Guggenheim | 212 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: To re-elect the following directors of the Company to hold office until our next annual meeting of stockholders and until their respective successors shall be elected and qualified or until their earlier resignation or removal: Dr. Miriam Kidron
ORAMED PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Dr. Miriam Kidron”): 10,011,623 for, 211,627 against, per its Form 8-K filed August 2, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The stockholders re-elected the following directors of the Company to hold office until the next annual meeting of stockholders and until their respective successors shall be elected and qualified or until their earlier resignation or removal.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 9 asset managers below reported 108,066 for, 11,889 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 74,906 | 0 | 0 | 0 | For |
| Dimensional | 17,901 | 0 | 0 | 0 | For |
| State Street | 0 | 11,889 | 0 | 0 | Against |
| American Century | 8,084 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 4,400 | 0 | 0 | 0 | For |
| Fidelity | 1,155 | 0 | 0 | 0 | For |
| Equitable | 711 | 0 | 0 | 0 | For |
| John Hancock | 697 | 0 | 0 | 0 | For |
| Guggenheim | 212 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
93% Majority: yes · of votes cast
Description as filed by funds: To re-elect the following directors of the Company to hold office until our next annual meeting of stockholders and until their respective successors shall be elected and qualified or until their earlier resignation or removal: Leonard Sank
ORAMED PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Leonard Sank”): 9,435,858 for, 764,562 against, per its Form 8-K filed August 2, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The stockholders re-elected the following directors of the Company to hold office until the next annual meeting of stockholders and until their respective successors shall be elected and qualified or until their earlier resignation or removal.”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 9 asset managers below reported 39,241 for, 80,714 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 0 | 74,906 | 0 | 0 | Against |
| Dimensional | 17,901 | 0 | 0 | 0 | For |
| State Street | 11,889 | 0 | 0 | 0 | For |
| American Century | 8,084 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 0 | 4,400 | 0 | 0 | Against |
| Fidelity | 1,155 | 0 | 0 | 0 | For |
| Equitable | 0 | 711 | 0 | 0 | Against |
| John Hancock | 0 | 697 | 0 | 0 | Against |
| Guggenheim | 212 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: To re-elect the following directors of the Company to hold office until our next annual meeting of stockholders and until their respective successors shall be elected and qualified or until their earlier resignation or removal: Nadav Kidron
ORAMED PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Nadav Kidron”): 10,007,284 for, 216,146 against, per its Form 8-K filed August 2, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The stockholders re-elected the following directors of the Company to hold office until the next annual meeting of stockholders and until their respective successors shall be elected and qualified or until their earlier resignation or removal.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 9 asset managers below reported 119,955 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 74,906 | 0 | 0 | 0 | For |
| Dimensional | 17,901 | 0 | 0 | 0 | For |
| State Street | 11,889 | 0 | 0 | 0 | For |
| American Century | 8,084 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 4,400 | 0 | 0 | 0 | For |
| Fidelity | 1,155 | 0 | 0 | 0 | For |
| Equitable | 711 | 0 | 0 | 0 | For |
| John Hancock | 697 | 0 | 0 | 0 | For |
| Guggenheim | 212 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: To re-elect the following directors of the Company to hold office until our next annual meeting of stockholders and until their respective successors shall be elected and qualified or until their earlier resignation or removal: Yehuda Reznick
ORAMED PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Yehuda Reznick”): 10,050,385 for, 138,618 against, per its Form 8-K filed August 2, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The stockholders re-elected the following directors of the Company to hold office until the next annual meeting of stockholders and until their respective successors shall be elected and qualified or until their earlier resignation or removal.”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 9 asset managers below reported 119,955 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 74,906 | 0 | 0 | 0 | For |
| Dimensional | 17,901 | 0 | 0 | 0 | For |
| State Street | 11,889 | 0 | 0 | 0 | For |
| American Century | 8,084 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 4,400 | 0 | 0 | 0 | For |
| Fidelity | 1,155 | 0 | 0 | 0 | For |
| Equitable | 711 | 0 | 0 | 0 | For |
| John Hancock | 697 | 0 | 0 | 0 | For |
| Guggenheim | 212 | 0 | 0 | 0 | For |
Combines 4 wordings of this item as funds reported it.
90% Approved · of votes cast
Description as filed by funds: To approve, on a non-binding advisory basis, the compensation of the Company's Named Executive Officers.
ORAMED PHARMACEUTICALS INC.’s own tally for this item (“2. Advisory Vote on the Compensation of the Company's Named Executive Officers”): 9,171,779 for, 1,016,334 against — passed, per its Form 8-K filed August 2, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The stockholders approved, on a non-binding, advisory basis, the compensation of the Company's Named Executive Officers as described in the proxy statement, including the "Compensation of Executive Officers and Directors" section, the related compensation tables and other narrative compensation dis…”
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 0 | 74,906 | 0 | 0 | Against |
| Dimensional | 0 | 17,901 | 0 | 0 | Against |
| State Street | 11,889 | 0 | 0 | 0 | For |
| American Century | 0 | 8,084 | 0 | 0 | Against |
| Blackstone Alternative Investment Funds | 0 | 4,400 | 0 | 0 | Against |
| Fidelity | 1,155 | 0 | 0 | 0 | For |
| Equitable | 0 | 711 | 0 | 0 | Against |
| John Hancock | 0 | 697 | 0 | 0 | Against |
| Guggenheim | 0 | 212 | 0 | 0 | Against |
Fund voting reports, all 9 managers: 13,044 for, 106,911 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Murchinson Ltd. | 1,595,996 | 0 | 0 | 0 | For |
| BOOTHBAY FUND MANAGEMENT, LLC | 775,263 | 0 | 0 | 0 | For |
| Two Sigma | 0 | 296,776 | 0 | 0 | Against |
| PNC BANK, NATIONAL ASSOCIATION | 219,200 | 0 | 0 | 0 | For |
| Renaissance | 0 | 80,647 | 0 | 0 | Against |
| DE Shaw | 0 | 50,989 | 0 | 0 | Against |
| TRUST CO OF OKLAHOMA | 18,000 | 0 | 0 | 0 | For |
| Fisher Asset Management, LLC | 0 | 14,781 | 0 | 0 | Against |
| State Street | 11,889 | 0 | 0 | 0 | For |
| American Century | 0 | 8,084 | 0 | 0 | Against |
| STIFEL NICOLAUS & CO INC \MO\ | 0 | 7,964 | 0 | 0 | Against |
| Connor, Clark & Lunn Investment Management Ltd. | 0 | 7,327 | 0 | 0 | Against |
| Crestwood Advisors Group, LLC | 5,700 | 0 | 0 | 0 | For |
| BOURGEON CAPITAL MANAGEMENT LLC | 5,627 | 0 | 0 | 0 | For |
| Janney Montgomery Scott LLC | 4,700 | 0 | 0 | 0 | For |
| Dimensional | 0 | 4,329 | 0 | 0 | Against |
| Williams Jones Wealth Management, LLC. | 4,000 | 0 | 0 | 0 | For |
| DUMONT & BLAKE INVESTMENT ADVISORS LLC | 3,500 | 0 | 0 | 0 | For |
| MERITAGE PORTFOLIO MANAGEMENT | 0 | 3,300 | 0 | 0 | Against |
| Northern Trust | 0 | 2,603 | 0 | 0 | Against |
| HighTower Advisors, LLC | 0 | 2,500 | 0 | 0 | Against |
| SCS Capital Management LLC | 2,500 | 0 | 0 | 0 | For |
| Clarkston Capital Partners, LLC | 1,705 | 0 | 0 | 0 | For |
| ENVESTNET ASSET MANAGEMENT INC | 1,460 | 0 | 0 | 0 | For |
| OneAscent Investment Solutions LLC | 1,313 | 0 | 0 | 0 | For |
Institutional-manager reports, all 56 managers: 2,661,968 for, 484,024 against. Showing the 25 largest; every one is in the interactive database (link above).
99.3% Approved · of votes cast
Description as filed by funds: To ratify the appointment of Kesselman & Kesselman, certified public accountants in Israel, a member of PricewaterhouseCoopers International Limited, as the independent registered public accounting firm of the Company for the 2024 fiscal year.
ORAMED PHARMACEUTICALS INC.’s own tally for this item (“3. Ratification of Independent Registered Public Accounting Firm for the 2024 Fiscal Year”): 17,323,361 for, 119,546 against — passed, per its Form 8-K filed August 2, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The stockholders ratified the appointment of Kesselman & Kesselman, certified public accountants in Israel, a member of PricewaterhouseCoopers International Limited, as the independent registered public accounting firm of the Company for the 2024 fiscal year.”
Support: 99.3% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 9 asset managers below reported 119,955 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 74,906 | 0 | 0 | 0 | For |
| Dimensional | 17,901 | 0 | 0 | 0 | For |
| State Street | 11,889 | 0 | 0 | 0 | For |
| American Century | 8,084 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 4,400 | 0 | 0 | 0 | For |
| Fidelity | 1,155 | 0 | 0 | 0 | For |
| Equitable | 711 | 0 | 0 | 0 | For |
| John Hancock | 697 | 0 | 0 | 0 | For |
| Guggenheim | 212 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 40,628,924 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BlackRock | 0.18% |
| 2 | Dimensional | 0.04% |
| 3 | State Street | 0.03% |
| 4 | American Century | 0.02% |
| 5 | Blackstone Alternative Investment Funds | 0.01% |
| 6 | Fidelity | <0.01% |
| 7 | Equitable | <0.01% |
| 8 | John Hancock | <0.01% |
| 9 | Guggenheim | <0.01% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Murchinson Ltd. | 3.93% |
| 2 | BOOTHBAY FUND MANAGEMENT, LLC | 1.91% |
| 3 | Two Sigma | 0.73% |
| 4 | PNC BANK, NATIONAL ASSOCIATION | 0.54% |
| 5 | Renaissance | 0.20% |
| 6 | DE Shaw | 0.13% |
| 7 | TRUST CO OF OKLAHOMA | 0.04% |
| 8 | Fisher Asset Management, LLC | 0.04% |
| 9 | State Street | 0.03% |
| 10 | American Century | 0.02% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Oramed Pharmaceuticals Inc. | 37.12% | 13D |
| BML Investment Partners, L.P. | 7.80% | 13G |
| Nadav Kidron | 7.67% | 13D |
| Aquamarine Financial (Cayman) Ltd | 5.04% | 13G |
| Leonard Braden Michael | 2.53% | 13G |
| Renaissance Technologies | 0.35% | 13F |
| Dimensional Fund Advisors | 0.35% | 13F |
| BlackRock | 0.23% | 13F |
| State Street | 0.16% | 13F |
| Two Sigma | 0.16% | 13F |
Percentages above are of 40,628,924 shares outstanding, as reported by ORAMED PHARMACEUTICALS INC. on its Form 10-Q dated May 9, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ORAMED PHARMACEUTICALS INC.’s 10-Q dated May 9, 2024. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
ORAMED PHARMACEUTICALS INC. proxy season coverage: 2024-2025 (this page).
proxyvotesnow.com, “ORAMED PHARMACEUTICALS (ORMP) 2024 Annual Meeting (2024-2025 season)”, https://proxyvotesnow.com/company/oramed-pharmaceuticals-inc/2025 (version of November 9, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.